Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NR2F6-silenced CAR-T
- Development stage
- Preclinical
- Lead developer
- Regen BioPharma
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
NR2F6-silenced CAR-T is an investigational genetically engineered cell therapy developed by Regen BioPharma for the treatment of solid tumors. The therapy combines chimeric antigen receptor (CAR) technology with the silencing of the nuclear receptor NR2F6, an intracellular immune checkpoint. By gene editing or silencing NR2F6, the therapy aims to restore CAR-T cell functionality, sustain a TCF1+ progenitor-exhausted phenotype, and enhance metabolic fitness and cytotoxic potency under chronic antigen exposure. This approach is specifically designed to overcome the immunosuppressive environment of solid tumors, allowing for more effective immune-mediated destruction of cancer cells by preventing T-cell exhaustion.
- Other names
- NR2F6-silenced CAR T cellsNR-2F6-silenced CAR T cellsNR 2F6-silenced CAR T cells
02
Targets
NR2F6 (Nuclear receptor subfamily 2 group F member 6)
Beyond the preview
Go deeper on NR2F6-silenced CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NR2F6-silenced CAR-T.